Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis

Authors: Jing-Yan Xu, Yun-Yu Sun, Min Zhou, Jing Wang, Qi-Guo Zhang, Xi-Hui Xu, Hui Zeng, Jian Ouyang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

To date, case–control studies on the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and follicular lymphoma have provided controversial results. To clarify the effect of MTHFR polymorphisms on the risk of follicular lymphoma, a meta-analysis of all case–control studies was performed. The fixed effects and random effects model showed that the C677T polymorphism was associated with a risk of follicular lymphoma among Caucasian populations, and A1298C polymorphism was associated with a risk of follicular lymphoma among Asian populations. Our pooled data suggest evidence for a major role of MTHFR polymorphisms in the carcinogenesis of follicular lymphoma.
Literature
1.
Matsuo K, Hamajima N, Suzuki R, Ogura M, Kagami Y, Taji H, et al. Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol. 2004;77(4):351–7.PubMedCrossRef
2.
3.
Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schöllkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15(2):258–65.PubMedCrossRef
4.
Smith MT, McHale CM, Wiemels JL, Zhang L, Wiencke JK, Zheng S. Molecular biomarkers for the study of childhood leukemia. Toxicol Appl Pharmacol. 2005;206(2):237–45.PubMedCrossRef
5.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–3.PubMedCrossRef
6.
Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299(20):2423–36.PubMedCrossRef
7.
Ismail SI, Ababneh NA, Khader Y, Abu-Khader AA, Awidi A. Methylenetetrahydrofolate reductase genotype association with the risk of follicular lymphoma. Cancer Genet Cytogenet. 2009;195(2):120–4.PubMedCrossRef
8.
Skibola CF, Forrest MS, Coppedé F, Agana L, Hubbard A, Smith MT, et al. Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood. 2004;104(7):2155–62.PubMedCrossRef
9.
Lee KM, Lan Q, Kricker A, Purdue MP, Grulich AE, Vajdic CM, et al. One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet. 2007;122(5):525–33.PubMedCrossRef
10.
Lightfoot TJ, Skibola CF, Willett EV, Skibola DR, Allan JM, Coppede F, et al. Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2999–3003.PubMedCrossRef
11.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
12.
13.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
14.
Berglund M, Enblad G, Turesson I, Edman V, Thunberg U. Folate-metabolizing genes in lymphoma patients from Sweden. Scand J Immunol. 2009;70(4):408–10.PubMedCrossRef
15.
Lim U, Wang SS, Hartge P, Cozen W, Kelemen LE, Chanock S, et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case–control study. Blood. 2007;109(7):3050–9.PubMed
16.
Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A. Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin’s lymphoma or multiple myeloma. Br J Haematol. 2003;120(6):1051–4.PubMedCrossRef
17.
Niclot S, Pruvot Q, Besson C, Savoy D, Macintyre E, Salles G, et al. Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas. Blood. 2006;108(1):278–85.PubMedCrossRef
18.
Kruszyna Ł, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodziński PP. Polymorphic variants of folate metabolism genes and the risk of laryngeal cancer. Mol Biol Rep. 2010;37(1):241–7.PubMedCrossRef
19.
Arslan S, Karadayi S, Yildirim ME, Ozdemir O, Akkurt I. The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep. 2011;38(2):991–6.PubMedCrossRef
20.
Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk. 2000;7:197–200.PubMed
21.
Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implication for cancer and neuronal damage. Proc Natl Acad Sci USA. 1997;94:3290–5.PubMedCrossRef
22.
Zing JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 1997;18:869–82.CrossRef
23.
Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578–92.PubMedCrossRef
Metadata
Title
Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis
Authors
Jing-Yan Xu
Yun-Yu Sun
Min Zhou
Jing Wang
Qi-Guo Zhang
Xi-Hui Xu
Hui Zeng
Jian Ouyang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0670-x

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant

Research Article

A support vector machine model for predicting non-sentinel lymph node status in patients with sentinel lymph node positive breast cancer

Research Article

Discussion of modifying stage IV gastric cancer based on Borrmann classification

Research Article

Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk

Research Article

Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma

Research Article

Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits